Novo Nordisk A/S is a Danish A/S based in Bagsværd, operating in the Manufacture of pharmaceutical preparations sector. Incorporated in 1931, the company has 27,896 employees and reported revenue of DKK 289.0bn in its latest annual filing.
Selskabet forpligtes ved underskrift (i) af to direktører i forening, (ii) af en direktør eller et bestyrelsesmedlem i forening med bestyrelsens formand eller næstformand eller (iii) af den samlede bestyrelse.
Company purpose
Selskabets formål er at forske i, udvikle, producere og markedsføre farmaceutiske, medicinske og tekniske produkter og ydelser samt anden dertil knyttet virksomhed efter bestyrelsens nærmere bestemmelse. Selskabet tilstræber at drive sin virksomhed på økonomisk, miljømæssigt og socialt ansvarlig vis.
In its most recent annual report (2025), Novo Nordisk A/S reported revenue of DKK 289.0bn, an increase of 10% on the year before. The figures on this page draw on 5 annual filings covering 2021 to 2025. The bottom line showed a net profit of DKK 100.4bn, and the EBITDA margin stood at 40.2%.
At the end of 2025, equity financed 39.9% of the balance sheet, and current assets covered short-term debt 0.7 times.
Frequently asked questions
What is the CVR number of Novo Nordisk A/S?
Novo Nordisk A/S is registered with CVR / Virk under CVR 24256790.
What is the revenue of Novo Nordisk A/S?
Novo Nordisk A/S reported revenue of DKK 289.0bn in 2025.
How many employees does Novo Nordisk A/S have?
Novo Nordisk A/S employs 27896 people as of the latest annual report.
Who is the CEO of Novo Nordisk A/S?
Maziar Doustdar is the CEO of Novo Nordisk A/S, in role since 2025.
Who is the chairman of Novo Nordisk A/S?
Lars Rebien Sørensen chairs the board of Novo Nordisk A/S, in role since 2025.
Where is Novo Nordisk A/S headquartered?
Novo Nordisk A/S's registered address is Novo Alle 1.
